Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Public ClinicalTrials.gov record NCT00004232. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Bone marrow and peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of bone marrow and peripheral stem cell transplantation in treating patients who have hematologic cancer.
Study identification
- NCT ID
- NCT00004232
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- filgrastim Biological
- cyclosporine Drug
- methylprednisolone Drug
- prednisone Drug
- allogeneic bone marrow transplantation Procedure
- peripheral blood stem cell transplantation Procedure
Biological · Drug · Procedure
Eligibility (public fields only)
- Age range
- 10 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 1999
- Primary completion
- Sep 30, 2002
- Completion
- Sep 30, 2002
- Last update posted
- May 31, 2012
1999 – 2002
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago | Illinois | 60611-3013 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Leukemia trials
Other public records listing Leukemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07227584: ALL Backbone in AYAs Recruiting
- NCT04898790: Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant Recruiting
- NCT06152809: CIML NK Cells With Venetoclax for AML Recruiting
- NCT06053268: Mindfulness Interventions to Improve Health Activation, Coping, and Stress Among Childhood Cancer Survivors Active, not recruiting
- NCT07714044: Rutgers University Study of the Genetics of Blood Cancers Not yet recruiting
- NCT06469307: Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00004232, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2012 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00004232 live on ClinicalTrials.gov.